WSJ – A wave of megadeal activity in Europe isn’t providing the trading opportunities many hedge funds had hoped for.
U.S. drug firm Pfizer Inc’s $120 billion attempt to buy U.K. rival AstraZeneca and General Electric’s proposed $17 billion purchase of French group Alstom’s power business are seen by many investors as kicking off a long-awaited boom in M&A in Europe.
